For Lab R&D Uses Only

Purity:               >98% (HPLC)

Product Description:

First-in-class potent and selective PPARG inverse agonist, displaying meaningful PPARG target gene silencing in UC cell lines as well as tumor regression in PPARG-amplified and RXRA-mutant UC xenograft models

Reference:

Abstract 2802: Development of a surrogate tissue pharmacodynamic (PD) assay for clinical use with FX-909, a novel inhibitor of the urothelial luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG) | Cancer Research | American Association for Cancer Research (aacrjournals.org)

Analytical data

Price & Availability